MENLO PARK, CA--(Marketwired - May 4, 2017) - Corcept Therapeutics Incorporated (
"There is growing awareness that even less severe degrees of hypercortisolism are harmful," said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. "As a result, physicians are increasingly screening patients whose metabolic and cardiovascular symptoms have not responded to conventional therapy and finding cases of previously undetected Cushing's syndrome."
In addition to viewing the posters described below, AACE attendees may attend "Evolving Paradigms of Hypercortisolism," a product theater talk by Ty Carroll, M.D. Corcept is a sponsor of the talk.
| Thursday, May 4, 2017 | |
| Poster #124 Screening of Diabetic Patients Using U500 Insulin Uncovers a High Percentage of Undiagnosed Hypercortisolism Consistent with Cushing Syndrome |
Joseph W. Mathews, M.D., FACE James J. Smith, PhD |
| Friday, May 5, 2017, 12:45 - 1:30pm Product Theater B |
|
| Evolving Paradigms of Hypercortisolism | Ty Carroll, M.D. |
| Friday, May 5, 2017 | |
| Poster #131 Medical Management of Mild Hypercortisolism and Primary Aldosteronism in a Patient with ACTH-Independent Macronodular Hyperplasia Presenting with Resistant Hypertension |
Sandi-Jo Galati, M.D. Michele Lamerson, RN, MS, CPNP |
| Poster #608 Improving Glycemic Control with Mifepristone in Cushing Syndrome Patients May Lead to Significant Weight-loss |
Adriana G. Ioachimescu, M.D., PhD, FACE Jonathan G. Ownby, M.D., FACE Nicole G. Greyshock, M.D., FACE Thomas C. Jones, M.D., FACE Gary S. Wand, M.D., PhD, FACE James J. Smith, PhD |
| Poster #725 Successful Medical Management with Mifepristone in a Patient with Occult Ectopic Cushing Syndrome |
Saima Farghani, M.D. Michele Lamerson, RN, MS, CPNP |
| Poster #836 Mifepristone Therapy Significantly Improved Insulin Resistance, Glycemic Control, and Weight Loss in a Patient with Cushing Disease Previously Treated with Pasireotide |
Jonathan G. Ownby, M.D., FACE James J. Smith, PhD |
| Poster #839 Mifepristone Reduced U500 Insulin Usage in a Patient with Cushing Disease and Normalized Concomitant Fatty Liver Disease and Retinopathy |
Kimberley A. Bourne, M.D., FACE James J. Smith, PhD |
About Corcept Therapeutics Incorporated
Corcept is a pharmaceutical company engaged in the discovery, development and commercialization of drugs that treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of cortisol. Korlym®, a first-generation cortisol modulator, is the company's first FDA-approved medication. The company has a portfolio of proprietary compounds that modulate the effects of cortisol but not progesterone. Corcept owns extensive intellectual property covering the use of cortisol modulators, including mifepristone, in the treatment of a wide variety of serious disorders, including Cushing's syndrome. It also holds composition of matter patents covering its selective cortisol modulators.
Contact Information:
CONTACT:
Charles Robb
Chief Financial Officer
Corcept Therapeutics
650-688-8783
www.corcept.com